CALIMAN, ENRICO
 Distribuzione geografica
Continente #
EU - Europa 900
NA - Nord America 812
AS - Asia 247
AF - Africa 3
SA - Sud America 1
Totale 1.963
Nazione #
US - Stati Uniti d'America 806
RU - Federazione Russa 431
IT - Italia 235
IE - Irlanda 94
SG - Singapore 73
HK - Hong Kong 64
CN - Cina 55
PL - Polonia 54
SE - Svezia 35
JO - Giordania 26
IN - India 24
FI - Finlandia 16
GB - Regno Unito 7
AT - Austria 6
DE - Germania 6
CA - Canada 5
CH - Svizzera 5
NL - Olanda 4
VN - Vietnam 4
FR - Francia 3
NO - Norvegia 3
CI - Costa d'Avorio 2
BE - Belgio 1
CL - Cile 1
EG - Egitto 1
MX - Messico 1
PK - Pakistan 1
Totale 1.963
Città #
Santa Clara 465
Dublin 94
Singapore 63
Warsaw 52
Hong Kong 46
Florence 45
Chandler 40
Ashburn 37
Rome 23
Milan 22
Shanghai 17
Fairfield 16
Moscow 15
Mumbai 15
Boardman 14
Helsinki 12
New York 12
Los Angeles 10
Seattle 10
Altamura 9
Woodbridge 9
Beijing 8
Lawrence 8
Pune 7
Brescia 6
Naples 6
Vienna 6
Kent 5
Bern 4
Boston 4
Houston 4
Lappeenranta 4
Princeton 4
Yubileyny 4
Zhengzhou 4
Alba 3
Ancona 3
Bremen 3
Oslo 3
Recanati 3
San Diego 3
San Marco Evangelista 3
Wilmington 3
Abidjan 2
Andover 2
Anguillara Sabazia 2
Brusaporto 2
Buffalo 2
Cambridge 2
Carmignano 2
Catania 2
Chennai 2
Cinisello Balsamo 2
Dong Ket 2
Faenza 2
Forlì 2
Formia 2
Genoa 2
Livorno 2
London 2
Mileto 2
Osimo 2
Ottawa 2
Palermo 2
Paris 2
Poggibonsi 2
Romola 2
Rufina 2
San Giovanni Valdarno 2
Scandicci 2
Toronto 2
Turin 2
Varese 2
Venice 2
Arezzo 1
Bagno A Ripoli 1
Bisceglie 1
Brussels 1
Chicago 1
Falls Church 1
Guangzhou 1
Hamburg 1
Harbin 1
Hillsboro 1
Kaluga 1
Krefeld 1
Lahore 1
Laurel 1
Marcallo con Casone 1
Medford 1
Newark 1
Norwalk 1
Nuremberg 1
Padova 1
Phoenix 1
Sasso Marconi 1
Shenyang 1
Siena 1
Stockton 1
Verona 1
Totale 1.212
Nome #
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. 200
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer 129
Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor) 102
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy 95
Chasing the target: New phenomena of resistance to novel selective ret inhibitors in lung cancer. updated evidence and future perspectives 94
Identification of predictive biomarkers of clinical benefits to immunotherapy in pre-treated advanced non-small cell lung cancer: a retrospective observational study 91
Induction chemotherapy followed by pleurectomy decortication and hyperthermic intraoperative chemotherapy (Hithoc) for early-stage epitheliod malignant pleural mesothelioma—a prospective report 91
Gender matters. Sex-related differences in immunotherapy outcome in patients with non-small cell lung cancer 78
Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions 76
In Regard to "Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations" 75
KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population 74
Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification 73
Alteration of the Nucleotide Excision Repair (NER) Pathway in Soft Tissue Sarcoma 73
Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study 72
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario 68
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 68
Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment 67
Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors 66
Liquid Biopsy and Non-small-cell Lung Cancer: Expecting More Fluid Management of Patients 63
Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer 63
KRAS-related miR-143 expression is associated with lymph node involvement and correlates with outcome in pancreatic adenocarcinoma patients 62
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 60
Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer 58
Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patients 55
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 43
Impact of natremia on metastatic non small cell lung cancer patients receiving immune checkpoint inhibitors 5
null 3
The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm? 1
Totale 2.005
Categoria #
all - tutte 8.104
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.104


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202036 0 0 0 0 0 6 6 6 6 5 6 1
2020/202143 3 7 0 6 3 3 3 4 4 6 0 4
2021/202227 0 2 1 0 0 2 2 5 0 2 3 10
2022/2023302 7 27 5 29 15 52 45 37 47 13 16 9
2023/2024361 10 14 27 19 24 49 24 77 11 19 35 52
2024/20251.197 64 164 96 283 408 182 0 0 0 0 0 0
Totale 2.005